Dr. Reddy’s Q4 FY25 Results – Explained.

India's leading pharma company Dr. Reddy’s Laboratories has announced strong results for the January–March 2025 quarter (Q4 FY25). Let’s break it down in simple terms: Key Numbers: • Profit: ₹1,594 crore — up by 22% compared to last year. • Revenue (Sales): ₹8,501 crore — grew by 20%. • EBITDA (Profit before interest & tax): ₹2,470 crore — up by 32%. • Profit margin: Improved to 29.1%. • Final dividend: ₹8 per share. What Helped the Growth? • Strong sales of generic medicines (low-cost versions of branded drugs). • New product launches, especially in the U.S.. • Good performance from its nicotine replacement therapy (NRT) products (helps people quit smoking). • Better performance in Europe, where sales more than doubled. Region-wise Performance: • North America: ₹3,560 crore (up 9%). • Europe: ₹1,280 crore (up 145%) — big boost from NRT. • India: ₹1,300 crore (up 16%). • Emerging Markets (Russia, CIS): ₹1,400 crore (up 16%). • API/Ingredient Sales (PSAI): ₹960 crore (up 16%). Full Year Highlights (FY25): • Total revenue: ₹32,554 crore (up 17%). • Full-year profit: ₹5,654 crore (up 2%). • Spent ₹2,740 crore on R&D (for new medicines & innovation). • Healthy cash in hand: ₹2,454 crore. Strategic Developments: • Filed 76 generic drug applications in the U.S.; 20 with potential first-to-file advantage. • Expanded biosimilars portfolio through global partnerships. • Received U.S. and UK regulatory approvals for multiple biosimilars. • Participated in India’s Jan Aushadi scheme for affordable medicines. • Divested its Shreveport, U.S. facility. • Hyderabad API plant received Voluntary Action Initiated (VAI) status from U.S. FDA. Stock Update: • Share price: ₹1,158 • 52-week high: ₹1,421 | Low: ₹1,020 • Market cap: ₹96,267 crore. In short, Dr. Reddy’s had a great quarter, driven by new products, strong global sales, and smart investments in the future. It’s focused on making affordable medicines while expanding in key markets like the U.S. and Europe.